Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.43.

EBIT: As of FY2026 Q2, the actual value is USD -30.23 M.

Financial Overview

Cash and Marketable Securities

enGene Therapeutics Inc. reported cash, cash equivalents, and marketable securities totaling $285,174 thousand as of April 30, 2026, which is an increase from $202,258 thousand as of October 31, 2025.

Operating Expenses

Total operating expenses for the three months ended April 30, 2026, were $31,968 thousand, an increase from $27,124 thousand for the same period in 2025. For the six months ended April 30, 2026, total operating expenses were $63,153 thousand, compared to $53,737 thousand for the six months ended April 30, 2025.

• Research and Development (R&D) ExpensesR&D expenses increased to $22,195 thousand for the three months ended April 30, 2026, from $20,209 thousand in the prior year period, primarily due to increased personnel and clinical costs related to the LEGEND trial, PPQ batch manufacturing, and Biologics License Application (BLA) submission preparation. For the six months ended April 30, 2026, R&D expenses were $44,450 thousand, up from $40,183 thousand for the same period in 2025.

• General and Administrative (G&A) ExpensesG&A expenses for the three months ended April 30, 2026, were $9,773 thousand, an increase from $6,915 thousand for the three months ended April 30, 2025, mainly due to the annualization of personnel-related costs and increased facility costs. For the six months ended April 30, 2026, G&A expenses totaled $18,703 thousand, compared to $13,554 thousand for the six months ended April 30, 2025.

Net Loss Attributable to Common Shareholders

The net loss attributable to common shareholders for the three months ended April 30, 2026, was $30,227 thousand, compared to $25,815 thousand for the three months ended April 30, 2025. For the six months ended April 30, 2026, the net loss was $59,979 thousand, compared to $50,431 thousand for the same period in 2025.

Other Financial Metrics

• Total Other Income, NetTotal other income, net, was -$1,741 thousand for the three months ended April 30, 2026, compared to -$1,549 thousand for the prior year period. For the six months ended April 30, 2026, it was -$3,174 thousand, compared to -$3,564 thousand for the same period in 2025.

• Provision for Income TaxThe company reported $0 thousand in provision for income tax for both the three and six months ended April 30, 2026, contrasting with $240 thousand and $258 thousand for the respective periods in 2025.

• Total Comprehensive LossTotal comprehensive loss for the three months ended April 30, 2026, was $30,526 thousand, compared to $25,509 thousand for the three months ended April 30, 2025. For the six months ended April 30, 2026, total comprehensive loss was $60,232 thousand, compared to $49,981 thousand for the same period in 2025.

• Unrealized Loss (Gain) on Available-for-Sale InvestmentsAn unrealized loss of $299 thousand was recorded for the three months ended April 30, 2026, compared to an unrealized gain of -$306 thousand in the prior year period. For the six months ended April 30, 2026, an unrealized loss of $253 thousand was recorded, compared to an unrealized gain of -$450 thousand for the same period in 2025.

Balance Sheet Highlights

As of April 30, 2026, total assets were $307,524 thousand, total liabilities were $52,356 thousand, and total shareholders’ equity was $255,168 thousand. These figures compare to total assets of $221,468 thousand, total liabilities of $53,758 thousand, and total shareholders’ equity of $167,710 thousand as of October 31, 2025.

Operational Metrics

• Workforce ReductionThe company implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.

• Estimated Restructuring CostsenGene Therapeutics Inc. estimates it will incur approximately $5.7 million to $6.4 million in restructuring costs, primarily for employee severance, benefits, and related costs.

• Non-Cash Stock-Based Compensation ExpenseAn additional approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense is expected, mainly due to accelerated vesting of stock options, with the majority anticipated in the second half of 2026.

• Cash Retention Bonus AwardsAggregate cash retention bonus awards of approximately $1.7 million will be paid to certain executive and non-executive employees upon achieving specific milestones.

• Chief Financial Officer Separation CostsThe outgoing Chief Financial Officer will receive a base salary continuation totaling $517,880 over twelve months, continued health insurance benefits, a prorated 2026 annual bonus, and accelerated vesting of certain equity awards due to the strategic restructuring.

• Clinical Trial Efficacy (LEGEND Pivotal Cohort 1)Interim data from LEGEND’s pivotal Cohort 1 showed a 54% complete response (CR) at any time in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS), with a low rate of progression to muscle invasive or more advanced disease (3.2%).

• Clinical Trial Safety (LEGEND Pivotal Cohort 1)A low percentage of patients experienced treatment-related adverse events leading to treatment interruption (2.4%) and treatment discontinuation (2.4%).

• New Cohort EnrollmentThe first patients have been enrolled in a new LEGEND cohort incorporating a short surfactant bladder rinse, which may enroll up to 80 patients globally.

• Suspension of Other CohortsEnrollment in LEGEND Cohorts 2a, 2b, and 3 has been stopped as part of cash conservation efforts, with reevaluation planned after discussions with the FDA in the second half of 2026.

Outlook / Guidance

enGene Therapeutics Inc. plans for 12-month complete response data from the LEGEND pivotal cohort and subsequent FDA engagement in the second half of 2026. The company also intends to initiate a Biologics License Application (BLA) filing for detalimogene in 2H 2026, with a potential FDA approval decision and platform designation anticipated in 2027. Pre-commercial activities are planned to support the commercial launch of detalimogene in 2027, if approved, while retaining necessary personnel and resources for these strategic goals.